We report the occurrence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with monosomy 7 transformation in two patients with chronic myeloid leukemia (CML) after imatinib and dasatinib treatment without previous exposure to chemotherapeutic agents. Case 1In May 2004, a 50-year-old man was diagnosed with CML accelerated phase. This was supported by blood basophils [20% and cytogenetic evidence of Philadelphia chromosome (Ph), t(9;22)(q34;q11) observed in 100% of metaphases analyzed. He was subsequently treated with imatinib (600 mg/day) and was followed. Four weeks later, the patient achieved complete hematological remission but had grade 2-skin toxicity. In December 2004, the patient developed grade 4 neutropenia and presented blastic crisis based on the presence of 20% of blast cells in his bone marrow. Inconclusive results was obtained with flow cytometric analysis for cell surface markers (immunophenotyping). Consequently, therapeutic regimen with Ara-C (40 mg/m 2 /day) was given together with imatinib (600 mg/day). Four months later, he developed a severe thrombocytopenia (grade 4) and treatments were discontinued. In June 2005, a new cytological investigation disclosed a picture of blastic crisis (100% of Ph?) and the patient considered resistant to imatinib. Despite the presence of thrombocytopenia, the patient was placed on dasatinib at an initial dose of 70 mg/BID. Because he did not achieve any cytogenetic response, dasatinib was progressively increased to 100 mg/BID. Complete cytogenetic response (CCR) was reached at 11 months (0% Ph? marrow metaphases) but the patient showed monosomy 7 in all Phmarrow metaphases cells and this was confirmed by the fluorescence in situ hybridization (FISH) technique. At this point, the complete blood cell count disclosed cytopenia and the myelogram did not show sign for dysplastic maturation in any cell lineages. Retrospective analysis of the sample collected prior to treatment with dasatinib did not show evidence of monosomy 7. In October 2006, the patient had lost the CCR and showed the presence of 25% of ph? and monosomy 7 in Ph-clone. In April 2007, blast cells were positive for CD34, CD13, CD33 and CD 64. G-banding karyotype showed 46,XY,t(9;22)(q34.1;q11.2)[5]/45,XY,-7[12]/46, XY[3] in 20 metaphases tested. The origin of blasts was not clear only by the karyotype. Accordingly, a diagnosis of AML was made and the patient received induction chemotherapy with Ara-C and daunorubicin. Despite treatment, the patient died 3 months later of refractory disease. Case 2A 22 year-old man was diagnosed with CML in 1997. The patient started treatment with µ interferon, but had failed to M. R. de Mello Conchon Á I. Bendit Á W.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.